The supreme court in India has rejected an attempt by the Swiss drug maker Novartis to patent an update to a cancer treatment called Gleevec — spelled Glivec in some markets. The decision is expected to have a big impact on pharmaceutical companies and health organizations far outside the borders of India.
The BBC’s Rahul Tandon joins Marketplace Morning Report host Jeremy Hobson to discuss the global pharmaceutical market and the new patent ruling.
India rejects Novartis cancer drug patent
No comments:
Post a Comment